THE USE OF A PAR-1 ANTAGONIST IN COMBINATION WITH A P2Y12ADP RECEPTOR ANTAGONIST FOR INHIBITION OF THROMBOSIS

摘要

The treatment and prevention of thrombotic events are provided through co-administration of PAR-1 and the P2Y12 ADP receptor antagonists. Combined inhibition of the PAR-1 and the P2Y12 ADP platelet activation pathways had synergistic antithrombotic and antiplatelet effects, as demonstrated in co-administration of SCH 602539 and cangrelor.